SCYNEXIS (LTS:0L49) Operating Cash Flow per Share : $1.51 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Operating Cash Flow per Share?

SCYNEXIS's operating cash flow per share for the three months ended in Mar. 2024 was $-0.08. SCYNEXIS's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for SCYNEXIS's Operating Cash Flow per Share or its related term are showing as below:

During the past 12 years, SCYNEXIS's highest 3-Year average Operating Cash Flow per Share Growth Rate was 34.90% per year. The lowest was 16.80% per year. And the median was 27.75% per year.

LTS:0L49's 3-Year OCF Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.25
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

SCYNEXIS Operating Cash Flow per Share Historical Data

The historical data trend for SCYNEXIS's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Operating Cash Flow per Share Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-6.80

-4.60

-2.07

-1.88

1.24

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.40	1.49	0.26	-0.16	-0.08

Competitive Comparison of SCYNEXIS's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Price-to-Operating-Cash-Flow falls into.

SCYNEXIS Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

SCYNEXIS's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	60.159	/	48.391
	=	1.24

SCYNEXIS's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-4.007	/	48.565
	=	-0.08

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.51

SCYNEXIS Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines